Mobia Medical, Inc. (NASDAQ:MOBI) Receives $20.25 Average PT from Analysts

Shares of Mobia Medical, Inc. (NASDAQ:MOBI) have received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $20.25.

A number of research analysts have issued reports on the stock. BTIG Research assumed coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $19.00 target price for the company. Wolfe Research assumed coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued an “outperform” rating for the company. Wall Street Zen cut shares of Mobia Medical from a “hold” rating to a “sell” rating in a report on Saturday. JPMorgan Chase & Co. assumed coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued an “overweight” rating and a $15.00 target price for the company. Finally, Zacks Research raised shares of Mobia Medical to a “hold” rating in a report on Wednesday, June 3rd.

Mobia Medical Price Performance

Shares of Mobia Medical stock opened at $12.70 on Tuesday. Mobia Medical has a 12-month low of $10.19 and a 12-month high of $14.77. The stock has a market capitalization of $420.18 million, a price-to-earnings ratio of 66.00 and a beta of 2.84.

Mobia Medical (NASDAQ:MOBI) last issued its earnings results on Thursday, June 4th. The company reported $999.00 earnings per share (EPS) for the quarter. The company had revenue of $12.07 million during the quarter.

Insiders Place Their Bets

In other Mobia Medical news, Director William T. Harrington purchased 533,333 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $7,999,995.00. Following the completion of the transaction, the director directly owned 2,006,716 shares of the company’s stock, valued at $30,100,740. This trade represents a 36.20% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Chase C. Leavitt purchased 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $45,000.00. Following the completion of the transaction, the insider directly owned 3,000 shares of the company’s stock, valued at approximately $45,000. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 1,268,332 shares of company stock valued at $19,024,980.